L-Valacyclovir-d8 is intended for use as an internal standard for the quantification of L-valacyclovir by GC- or LC-MS. L-Valacyclovir is an L-valyl prodrug form of the antiviral guanosine analog acyclovir . L-Valacyclovir inhibits herpes simplex virus type 1 (HSV-1) replication (IC50 = 0.84 µM in Vero cells).1 It is more potent than the stereoisomer D-valacyclovir but less potent than acyclovir in vitro, however, it is rapidly converted to acyclovir in vivo.2 Formulations containing L-valacyclovir have been used in the treatment of HSV-1 infections.
1.Beauchamp, L.M., Orr, G.F., de Miranda, P., et al.Amino acid ester prodrugs of acyclovirAntivir. Chem. Chemother.3(3)157-164(1992) 2.Beutner, K.R.Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacyAntiviral Res.28(4)281-290(1995)